Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means. This episode provides a clear-eyed analysis of ...
A titanium-based lithium coin-cell battery reduced visible esophageal tissue injury compared with traditional batteries in a porcine model. The protective battery still generated alkaline hydroxide, ...
A Nemours program trained pediatric residents to conduct autism evaluations, improving confidence and helping families access care sooner. Long waits for autism evaluations continue to delay diagnosis ...
An expert reviews the pediatric IBS-C label expansion for linaclotide, discusses how it addresses historical evidence gaps, and outlines practical considerations for patient selection, counseling, and ...
The FDA approved the first generic version of rifapentine tablets, previously marketed as Priftin. Rifapentine is indicated for active pulmonary tuberculosis in patients aged 12 years and older and ...
Any infant who consumed Nara Organics Whole Milk Organic Powdered Infant Formula and presents with constipation, poor feeding, hypotonia, loss of head control, or facial weakness should be evaluated ...
The FDA's Warning Letter identifies the SNOO X-Small and X-Large sleep sacks as unauthorized modifications to an FDA-cleared device; clinicians should caution families to discontinue use of these ...
The US Food and Drug Administration (FDA) has cleared Dexcom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor (CGM) for children, expanding the integrated CGM ...
The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally. The FDA has approved ...
The FDA approved lebrikizumab-lbkz (EBGLYSS) for a maintenance dosing regimen of 250 mg every 8 weeks in adults and adolescents ≥12 years and ≥40 kg with moderate-to-severe atopic dermatitis, allowing ...
The FDA has accepted for review Takeda's sBLA for IV vedolizumab in patients ages 2 and older with moderately to severely active UC or Crohn's disease; a regulatory decision is expected by Q1 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results